Abstract: The usage of non-halal plasma transglutaminase to improve the gelling properties of surimi isprohibited for Muslim consumers. The objective of this study is to detect non-halal plasma transglutaminasein surimi products. A total of 12 samples were tested using DEAE, Unosphere Q and BioScale Macroprep HighQ columns and further confirmed by Sandwich ELISA method. Three different monoclonal antibody (MAbs)species which were bovine, chicken and porcine were used to observe the reaction against the samples. Thereactivity of the antibody against the antigen was defined in a certain range of cutoff value that is very strong,strong, moderate, weak and negative. By using the MAbs of the different species, the result showed S1, S2 andS3 did not contain transglutaminase from bovine while the other samples did. Six samples which were S1, S2,S3, S8, S11 and S12 selected in the ELISA procedure had a very strong reaction with transglutaminase fromporcine species. For MAbs of chicken species, S12 has a weak reactivity while other samples showed verystrong and strong reaction of transglutaminase. The sandwich ELISA can be a useful method to detect thepresence of transglutaminase in surimi-based products, which is derived from blood of different species ofmammalian animals. Further study should be done to optimize the specificity of antibody used in theconfirmation of TGase in surimi. Key words: Surimi Monoclonal antibody Textural Sandwich ELISA

Abstract:The Halal pharmaceutical industry is relatively new and offers untapped opportunities to be furtherdeveloped. The objective of this study is to develop Halal certification modules and training programmes tocater to the differing groups of auditors, industry, health professionals and consumers. In January 2012,Standards Malaysia announced the debut of the new Malaysian Standard for Halal pharmaceuticals, MS2424:2012, a great leap forward in allowing pharmaceutical manufacturers to obtain Halal compliance certificationfor their products. With the advent of this Halal standard, there is now a growing demand from thepharmaceutical industry for training programmes in order to apply and achieve Halal certification for theirproducts. The MS 2424:2012 standard is studied in depth and organizations involved in the development areconsulted to develop appropriate training modules. Experts from various fields including medicine, dentistry,shariah, science and others are recruited and trained to become module instructors. The graduate internsinvolved in the project undergo attachments and extensive training in view of upscaling into halalpharmaceutical executives. The launch of the modules and training programme is expected to contributesignificantly to greater ability of the pharmaceutical industry to cater to Halal requirements and thus satisfypublic demand, while at the same time promising higher sales and export potential. There is a growingawareness and thus corresponding demand for medicines that comply with shariah requirement from the Muslimummah or public. Thus, the research perspective of halal pharmaceutical industry in Malaysia becomes wider.The development of the training module is an effort to facilitate the pharmaceutical industry to comply with theshariah requirements. Key words: Pharmaceuticals Halal Training Module MS2424:2012 Certification